Due to the possible cholesterol issues, moderate anabolic steroid cycles may be best served with SERM’s in order to protect against estrogenic related side effects. SERM’s will not negatively affect cholesterol; in fact, SERM’s like Nolvadex have been shown to promote healthy cholesterol levels due to their ability to act as estrogen in the liver. However, for many a SERM won’t be enough and AI’s will be necessary. If an AI is necessary, the individual should limit his use and only use as much as is actually needed. Some have suggested that a 10mg per day dosing of Nolvadex along with your Arimidex use may actually aid in cholesterol management.
Patients enrolled in this study had a median age of 62 years (range 28 to 89). The majority of patients were White (78%), and most patients had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 (98%). Forty-eight percent of patients had received chemotherapy and 56% had received antihormonal therapy in the neoadjuvant or adjuvant setting prior to their diagnosis of advanced breast cancer. Thirty-seven percent of patients had no prior systemic therapy in the neoadjuvant or adjuvant setting. The majority of patients (97%) had metastatic disease. Twenty-three percent of patients had bone only disease, and 49% of patients had visceral disease.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: 18 Years and older (Adult, Senior) Sexes Eligible for Study: Female Gender Based Eligibility: Yes Accepts Healthy Volunteers: No Criteria Inclusion Criteria: